HRP20191368T1 - Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora - Google Patents

Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora

Info

Publication number
HRP20191368T1
HRP20191368T1 HRP20191368T HRP20191368T1 HR P20191368 T1 HRP20191368 T1 HR P20191368T1 HR P20191368 T HRP20191368 T HR P20191368T HR P20191368 T1 HRP20191368 T1 HR P20191368T1
Authority
HR
Croatia
Prior art keywords
ifnalpha
modulators
responses
amide
alkyl
Prior art date
Application number
Other languages
English (en)
Inventor
Ryan M Moslin
David S Weinstein
Stephen T Wrobleski
Yanlei Zhang
John S Tokarski
Michael E Mertzman
Chunjian Liu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HRP20191368T1 publication Critical patent/HRP20191368T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20191368 2013-11-07 2019-07-30 Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora HRP20191368T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ARP130104090A AR094537A1 (es) 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW102140574A TWI582077B (zh) 2013-11-07 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
VE140013 2013-11-11
PCT/US2014/011769 WO2015069310A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Publications (1)

Publication Number Publication Date
HRP20191368T1 true HRP20191368T1 (hr) 2019-11-29

Family

ID=56241743

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191368 HRP20191368T1 (hr) 2013-11-07 2019-07-30 Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora

Country Status (31)

Country Link
US (2) US9663467B2 (hr)
EP (2) EP3590926A1 (hr)
JP (1) JP6312823B2 (hr)
KR (1) KR102186633B1 (hr)
CN (1) CN106660960B (hr)
AR (1) AR094537A1 (hr)
AU (1) AU2014347275B2 (hr)
CA (1) CA2930060C (hr)
CL (1) CL2016001101A1 (hr)
CY (1) CY1122065T1 (hr)
DK (1) DK3066078T3 (hr)
EA (1) EA033272B1 (hr)
ES (1) ES2738826T3 (hr)
HK (1) HK1226400A1 (hr)
HR (1) HRP20191368T1 (hr)
HU (1) HUE046052T2 (hr)
IL (1) IL245448B (hr)
LT (1) LT3066078T (hr)
MA (1) MA39001A1 (hr)
MX (1) MX369394B (hr)
MY (1) MY174453A (hr)
NZ (1) NZ720710A (hr)
PE (1) PE20160961A1 (hr)
PH (1) PH12016500779A1 (hr)
PL (1) PL3066078T3 (hr)
PT (1) PT3066078T (hr)
RS (1) RS59125B1 (hr)
SI (1) SI3066078T1 (hr)
TN (1) TN2016000153A1 (hr)
TW (1) TWI582077B (hr)
WO (1) WO2015069310A1 (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074670A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CA3039202A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MA46620A (fr) 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
JP7012082B2 (ja) * 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤
JP7046092B2 (ja) * 2016-12-13 2022-04-01 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物
BR112019020163A2 (pt) 2017-03-30 2020-04-22 Bristol-Myers Squibb Company forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazina-3-carboxamida
MX2019012929A (es) 2017-05-11 2020-01-14 Bristol Myers Squibb Co Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).
CN111315737A (zh) * 2017-11-21 2020-06-19 百时美施贵宝公司 经砜吡啶烷基酰胺取代的杂芳基化合物
CA3090842A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
MX2021001581A (es) * 2018-08-16 2021-04-19 Innate Tumor Immunity Inc Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
CN113490664A (zh) 2018-10-22 2021-10-08 埃斯克疗法股份有限公司 Tyk2抑制剂和其用途
WO2020092196A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
US20230150979A1 (en) * 2019-01-30 2023-05-18 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
AU2019443366A1 (en) 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
US20220204495A1 (en) * 2019-05-03 2022-06-30 Valo Health, Inc. Inhibiting trabid
JP2022541772A (ja) * 2019-07-16 2022-09-27 ブリストル－マイヤーズ スクイブ カンパニー インターロイキンの調節におけるプロドラッグ
JP2023524361A (ja) 2020-03-11 2023-06-12 ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド Ｔｙｋ２活性を阻害する複素環式化合物
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
KR20230004612A (ko) * 2020-04-14 2023-01-06 고사머 바이오 서비시즈 인코포레이티드 염증성 질병의 치료를 위한 치환된 피리딘
EP4143180A1 (en) * 2020-04-28 2023-03-08 Bristol-Myers Squibb Company Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
JP2024510274A (ja) * 2021-03-16 2024-03-06 アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド アミノヘテロアリール化合物および組成物
AU2022268464A1 (en) * 2021-05-04 2023-12-21 Shanghai Zheye Biotechnology Co. Ltd. Nitrogen-containing heterocyclic pyridine compound
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
AU2022350509A1 (en) 2021-09-23 2024-04-04 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023109954A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023213308A1 (zh) * 2022-05-05 2023-11-09 苏州隆博泰药业有限公司 酰胺取代的杂环化合物及其医药用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024042361A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2024042363A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2794569B1 (en) * 2011-12-21 2017-05-10 Biota Europe Ltd Heterocyclic urea compounds
RU2014130214A (ru) * 2011-12-23 2016-02-10 Целльзом Лимитид Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
WO2014074670A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物

Also Published As

Publication number Publication date
JP6312823B2 (ja) 2018-04-18
EP3066078B1 (en) 2019-05-22
ES2738826T3 (es) 2020-01-27
CA2930060C (en) 2020-03-24
TN2016000153A1 (en) 2017-10-06
EA201690865A1 (ru) 2017-01-30
PH12016500779A1 (en) 2016-05-30
MY174453A (en) 2020-04-20
TWI582077B (zh) 2017-05-11
IL245448A0 (en) 2016-06-30
WO2015069310A1 (en) 2015-05-14
PL3066078T3 (pl) 2019-10-31
PT3066078T (pt) 2019-08-01
US20160280649A1 (en) 2016-09-29
AR094537A1 (es) 2015-08-12
IL245448B (en) 2019-08-29
LT3066078T (lt) 2019-07-25
MA39001A1 (fr) 2017-10-31
EP3066078A1 (en) 2016-09-14
HUE046052T2 (hu) 2020-02-28
MX2016005853A (es) 2016-07-13
US9987266B2 (en) 2018-06-05
TW201420572A (zh) 2014-06-01
CN106660960A (zh) 2017-05-10
KR102186633B1 (ko) 2020-12-03
MX369394B (es) 2019-11-07
CY1122065T1 (el) 2020-11-25
CA2930060A1 (en) 2015-05-14
NZ720710A (en) 2019-12-20
DK3066078T3 (da) 2019-08-26
KR20160071475A (ko) 2016-06-21
EA033272B1 (ru) 2019-09-30
AU2014347275A1 (en) 2016-06-23
US20170209426A1 (en) 2017-07-27
EP3590926A1 (en) 2020-01-08
HK1226400A1 (zh) 2017-09-29
CN106660960B (zh) 2019-11-08
BR112016010172A2 (pt) 2017-08-08
JP2017512749A (ja) 2017-05-25
RS59125B1 (sr) 2019-09-30
US9663467B2 (en) 2017-05-30
PE20160961A1 (es) 2016-10-08
CL2016001101A1 (es) 2016-12-16
SI3066078T1 (sl) 2019-08-30
AU2014347275B2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
HRP20191368T1 (hr) Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora
HUS2300025I1 (hu) Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai
IL238554A0 (en) Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses
EP3065875A4 (en) Bioprinter and methods of using same
EP3149151A4 (en) Sample preparation devices and methods
HK1210398A1 (en) Devices and methods facilitating sleeve gastrectomy and other procedures
PT2988756T (pt) Formulação de um meio de contraste e seu processo de preparação associado
GB201312318D0 (en) Novel methods and compounds
EP2968380A4 (en) Methods and devices for affecting nerve function
PL3154351T3 (pl) Kombinacje związków czynnych zawierające cyflufenamid i spiroksaminę
EP3073818A4 (en) Cheese-making methods and apparatuses
EP3146869A4 (en) Air-circulating mat
AU2014902782A0 (en) Baby patting device
AU2013901167A0 (en) Health Preservation